Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:47:41.472Z.
Consensus retrieved: 2026-10-06T14:52:08.711Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:47:41.472Z.
Quote observation: 2026-10-06T17:43:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c2871aed35905ca893ff96a4b2ab646902ae69530b401aedab5470ff00d0a486
FORWARD PE RATIO
N/A
Optimi Health Corp.
Market Cap
$13.33M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Optimi Health Corp. (OPTH) | $13.33M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.62M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.62M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.35M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.76M | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $13.16M | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.95M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.14M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.21M | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.62M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-09-30
Consensus estimates for this stock are reported in CAD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
